Friday January 10, 2020 0 comments
GOLDEN -- PharmaJet, maker of needle-free injection technology, announced the Invectys Phase I clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system was a success.
The vaccine was delivered to patients either by intradermal injection followed by electroporation, or by intradermal needle-free injection using the PharmaJet Tropis device.
It is the first in-human study of INVAC-1, an immune-therapeutic DNA vaccine for the treatment of cancer.
The study, entitled A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors, was published in Clinical Cancer Research on Nov. 19, 2019 (DOI: 10.1158/1078-0432.CCR-19-1614).
The publication cites that "administration with Tropis is immunogenic and able to elicit hTERT specific CD4 and CD8 immune responses in patients. This represents a great improvement for patient care as administration by Tropis is easy to perform, reliable and precise.
“Moreover, this system is cost-effective and brings increased comfort for patients with lower pain and better local tolerance (compared to electroporation)."
Invectys chose the PharmaJet Tropis for its ongoing Phase II study for Chronic Lymphocytic Leukemia in the U.S. and Europe, in addition to solid tumor studies in 2020.
"We are pleased with the continued success of PharmaJet Tropis in clinical studies with nucleic acid (DNA or RNA) vaccine delivery and look forward to its ongoing use in future studies," said Ron Lowy, PharmaJet chair and CEO.